Investors File Securities Class Action Lawsuit Against Medivation, Inc. (“MDVN”) Over Experimental Drug Dimebon
A securities class action lawsuit was filed against Medivation, Inc. (“MDVN”) in the United States District Court for the Northern District California on behalf of purchasers of Medivation, Inc. (“MDVN”) stock since July 2008, for violations of the federal securities laws, according to a securities class action lawsuit filing news report.
The Medivation, Inc. securities class action lawsuit complaint reportedly alleges that defendants violated federal securities laws by misrepresenting the effectiveness of its experimental drug, Dimebon.
If You Have Thoughts On The Medivation, Inc. Class Action Lawsuit, Share Your Class Action Comments Below.